Literature DB >> 23574120

Implementing a Death with Dignity program at a comprehensive cancer center.

Elizabeth Trice Loggers1, Helene Starks, Moreen Shannon-Dudley, Anthony L Back, Frederick R Appelbaum, F Marc Stewart.   

Abstract

BACKGROUND: The majority of Death with Dignity participants in Washington State and Oregon have received a diagnosis of terminal cancer. As more states consider legislation regarding physician-assisted death, the experience of a comprehensive cancer center may be informative.
METHODS: We describe the implementation of a Death with Dignity program at Seattle Cancer Care Alliance, the site of care for the Fred Hutchinson-University of Washington Cancer Consortium, a comprehensive cancer center in Seattle that serves the Pacific Northwest. Institution-level data were compared with publicly available statewide data from Oregon and Washington.
RESULTS: A total of 114 patients inquired about our Death with Dignity program between March 5, 2009, and December 31, 2011. Of these, 44 (38.6%) did not pursue the program, and 30 (26.3%) initiated the process but either elected not to continue or died before completion. Of the 40 participants who, after counseling and upon request, received a prescription for a lethal dose of secobarbital (35.1% of the 114 patients who inquired about the program), all died, 24 after medication ingestion (60% of those obtaining prescriptions). The participants at our center accounted for 15.7% of all participants in the Death with Dignity program in Washington (255 persons) and were typically white, male, and well educated. The most common reasons for participation were loss of autonomy (97.2%), inability to engage in enjoyable activities (88.9%), and loss of dignity (75.0%). Eleven participants lived for more than 6 months after prescription receipt. Qualitatively, patients and families were grateful to receive the lethal prescription, whether it was used or not.
CONCLUSIONS: Overall, our Death with Dignity program has been well accepted by patients and clinicians.

Entities:  

Mesh:

Year:  2013        PMID: 23574120     DOI: 10.1056/NEJMsa1213398

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  23 in total

1.  [Physician-assisted suicide is not a failure of palliative care].

Authors:  Ahmed Al-Awamer
Journal:  Can Fam Physician       Date:  2015-12       Impact factor: 3.275

2.  Palliative care: Secobarbital in Seattle--why lose sleep?

Authors:  Harvey Max Chochinov
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

3.  Is physician-assisted death in anyone's best interest? Yes.

Authors:  James Downar
Journal:  Can Fam Physician       Date:  2015-04       Impact factor: 3.275

4.  Care, compassion, respect.

Authors:  James Downar
Journal:  CMAJ       Date:  2014-10-27       Impact factor: 8.262

5.  Whither palliative care?

Authors:  C L Watt; J Downar
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

6.  How California Prepared for Implementation of Physician-Assisted Death: A Primer.

Authors:  Laura A Petrillo; Elizabeth Dzeng; Krista L Harrison; Lindsay Forbes; Benjamin Scribner; Barbara A Koenig
Journal:  Am J Public Health       Date:  2017-04-20       Impact factor: 9.308

7.  Premature closure of the debate.

Authors:  James Downarm; Tracey M Bailey; Jennifer Kagan
Journal:  CMAJ       Date:  2014-07-08       Impact factor: 8.262

8.  Of carts and horses.

Authors:  James Downar; Tracey M Bailey; Jennifer Kagan
Journal:  CMAJ       Date:  2014-05-13       Impact factor: 8.262

9.  Physician-Assisted Suicide and Euthanasia in the ICU: A Dialogue on Core Ethical Issues.

Authors:  Ewan C Goligher; E Wesley Ely; Daniel P Sulmasy; Jan Bakker; John Raphael; Angelo E Volandes; Bhavesh M Patel; Kate Payne; Annmarie Hosie; Larry Churchill; Douglas B White; James Downar
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

10.  Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist.

Authors:  Rebecca A Spence; Charles D Blanke; Thomas J Keating; Lynne P Taylor
Journal:  J Oncol Pract       Date:  2017-09-15       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.